Exceptional Response to Pembrolizumab and Trastuzumab in a Heavily Pretreated Patient With HER2-Positive TMB-H and MSI-H Metastatic Breast Cancer

JCO Precis Oncol. 2021 Nov:5:904-909. doi: 10.1200/PO.20.00361.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / genetics
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology
  • Female
  • Humans
  • Microsatellite Instability
  • Middle Aged
  • Mutation
  • Neoplasm Metastasis
  • Receptor, ErbB-2 / biosynthesis
  • Trastuzumab / therapeutic use*

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • pembrolizumab
  • Receptor, ErbB-2
  • Trastuzumab